Navigation Links
Golden Meditech Announces HK$217 Million Private Equity Financing for Hospital Subsidiary
Date:10/1/2009

HONG KONG, Oct. 1 /PRNewswire-Asia/ -- Golden Meditech Company Limited ("Golden Meditech" or the "Group"; Stock Code: 801.HK), a leading hi-tech medical device and healthcare service corporation in China, today announced that its hospital subsidiary - Golden Meditech Hospital Group (GMHG) has entered into an agreement to issue senior 5% redeemable convertible notes due in 2014 with an aggregate principal amount of US$28 million (equivalent to approximately HK$217 million). The monies raised will be used to accelerate business developments in China.

Under the agreement, GMHG will issue 15,747 new shares to investors upon full conversion, valuing the entire GMHG in excess of US$200 million. Upon full conversion, the note holder will hold approximately 13.61% of enlarged share capital of GMHG, and our holdings in GMHG will be diluted from current 60% to 51.8%.

Golden Meditech completed its strategic entry into China's hospital management and service market in June this year, and now owns the first nationwide management license granted by China government to a foreign entity.

Mr. KAM Yuen, Chairman of Golden Meditech said, "China's hospital management industry embraces a new era of development as the new medical reform aimed at separating hospital ownership and management and improving hospital operational efficiency will transform the hospital market entirely."

The successful private equity financing of GMHG have brought in renowned strategic investors from the healthcare industry. Through such a strategic collaboration, the group expects to accelerate the development of its hospital management operations in China, which in return generate significant profit contribution as well, he emphasized.

"Besides accelerating its expansion plan in China, this successful private equity financing will help create synergies effects between GMHG and other businesses we are currently operating. Such a move will help not only enhance our competitiveness, but also strengthen our strategic presence as one of the leading players in China's healthcare industry," said Mr. KAM.

Golden Meditech Company Limited (the "Company" or "Golden Meditech"; stock code: 801), together with its subsidiaries (collectively referred to as the "Group"), is a leading healthcare corporation in China. Golden Meditech operates an integrated portfolio of healthcare businesses including medical devices, healthcare services and natural herbal medicines. It has gained dominant market positions in all business segments. The first healthcare company listed outside Mainland China, the Group debuted on the Growth Enterprise Market (GEM) of the Stock Exchange of Hong Kong in December 2001 and migrated its listing to the Main Board in June 2009. The Group's mission is to contribute to people's health and welfare through the development and generalization of advanced medical technology and healthcare services, and to create value for its shareholders.

For enquiries, please contact the investor relations department of Golden Meditech Company Limited.

Address: 48/F., Bank of China Building, 1 Garden Road, Central, Hong Kong

Tel: +852 3605 8138

Fax: +852 3605 8181

Email: ir@goldenmeditech.com

SOURCE Golden Meditech Company Limited


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
2. China Sky One Medical, Inc. Signs Agreement with Taiwan Golden Biotechnology Corp. on Development of New Anti-Cancer Drug
3. Golden scales
4. Golden nanocrown
5. Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross to Join Lifetime Networks and Members of Congress From Both Parties at Capitol Hill Press Conference
6. Bioinformatics Expert Dr. Jiaan Yang Joins Sundia MediTech With Innovative PFSC Technology
7. Sundia MediTech Appoints Dr. Tong Xu as VP of Process Chemistry
8. Sundia MediTech in Deloitte Technology Fast 500 Asia Pacific List
9. Sundia MediTech and Xcovery Announce Big Success in Drug Discovery
10. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
11. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the launch of ... on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO Summit ... peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a unique set ...
(Date:3/22/2017)... Milwaukee, WI (PRWEB) , ... March 22, 2017 , ... ... federal scientific research agencies as outlined in the Administration’s recently published fiscal year 2018 ... for the National Institutes of Health (NIH) by $5.8 billion or roughly 20% of ...
(Date:3/22/2017)... , March 22, 2017  Personal Genome ... its cancer testing contract with the U.S. Department ... tumor profiling assay with the company,s new CancerSELECT ... comprehensive, clinically actionable pan-cancer profiling test that includes ... assess potential patient response to checkpoint inhibitor immunotherapies. ...
(Date:3/20/2017)... ... , ... SSCI and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, are ... the Parenteral Drug Association (PDA), the New York Interphex Show will open on March ... more than 625 exhibitors, the educational and networking opportunities are extremely valuable. INTERPHEX is ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the leading ... The Prince,s Trust to uncover insights to support its ... Trust. The UK,s leading youth charity will be using ... results and get a better understanding of the topics and issues ... ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
Breaking Biology News(10 mins):